|
|
|
|
|
|
| Preventing HIV |
| Treating HIV |
| Living with HIV |
| For service providers |
| For health care providers |
| Access our services |
| Find organizations |
| News and events |
| About CATIE |
| Site map |
| Home |
| CATIE Ordering Centre |
TreatmentUpdate 176Volume 22 Issue 1 2010 January I ANTI-HIV AGENTS - A. Massive change in U.S. treatment guidelinesFor many years the United States Department of Health and Human Services (DHHS) has been producing guidelines to help physicians when they are considering options for the treatment of their HIV-positive patients. The DHHS guidelines are closely watched because they often set the standard to which guidelines in other countries aspire. For help writing the guidelines, the DHHS crafted a panel of leading infectious disease and other specialists who have experience in the research and treatment of HIV infection. On December 1, 2009, the DHHS released the latest version of the guidelines for the treatment of adults and adolescents with HIV. There have been major revisions to the guidelines, resulting in a shift toward much earlier treatment. Usually the guidelines inform physicians which groups of drugs are best used. In another major departure from recent practice, the guidelines now recommend specific regimens of anti-HIV drugs. This may simplify physician decision-making—after all, more than 20 drugs for the treatment of HIV are available in a confusing array of possible combinations. However, in privileging just a few regimens over others, the panel courts controversy. The DHHS also makes additional guidelines on these topics:
These and other guides are available at: www.aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines&Search=On In this issue of TreatmentUpdate, we highlight key changes in the guidelines, particularly in the area of starting treatment. Created on: 2010 January 25 Author: Hosein SR |
|
| |
|
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE | |